EUCTR2010-023755-28-IT进行中（未招募）不适用
se of doxorubicin liposomiale not peghilata (MYOCET) as second-line chemotherapy in epithelial ovarian carcinoma: Carboplatin + Myocet in patients Platinum sensitive or Myocet as single agent in patients Platinum resistant - DOXO
IVERSITA` CAMPUS BIOMEDICO0 个研究点开始时间: 2010年12月1日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. Patients suffering from recidivism of epithelial ovarian carcinoma, confirmed histologically, who had disease progression at least 6 months after the end of the first-line therapy with Platinum in single regime in combination.
- •2. all patients must have measurable disease or assessed. For measurable disease is defined as an injury that can be evaluated in clinical inspection or through diagnostic imaging ... For disease assessed means biopsy performed during surgery of second look, positive for neoplasia, despite ongoing intervention and through diagnostic imaging have not been observed occurrence of the disease, moreover with a CA125 negative. .
- •3. Patients with ECOG Performance status (Oken MM, 1982) = 2
- •4. patients were hospitalized recently for complications from surgery or chemotherapy. In particular, the patient should not have infectious events in progress. If the progression has occurred in the course of previous chemotherapy, waiting for recruitment in the Protocol must be at least 4 weeks.
- •5. previous Therapy:
- •-Patients must have made a previous chemotherapy regime containing Carboplatin, cisplatin or other drug made of Platinum.
- •-The patient must have previously signed up at least one chemotherapy regimen.
- •6. the patient shall have suitable values:
- •Marrow: WBC Features greater than or equal to 3,000/ul. Platelets are greater than or equal to 100, 000/ul. Granulocytes greater than or equal to 1,500/ul.
- •Kidney function: creatinine less than or equal to 1.5 mg/dl: hepatic Bilirubin, SGOT and SGPT less than or equal to 1.5 times the norm. Alkaline phosphatase less than or equal to 2.5 the norm.
- •Ventricular ejection fraction (LVEF) 50% in echocardiography.
- •7. Patients who signed informed consent.
- •8. patients who respond to parametric described in section 7.0.
- •9. having Patients over the age of 18 years.
- •10. patients with negative pregnancy test.
- •11. patients with a life expectancy of more than 12 months
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Platinum-resistant Patients, or patients who have recidivato within 6 months of the deadline by terpia platinum based on even during therapy.
- •1b. Platinum-sensitive Patients.
- •2. patients who have tumors gynecological not concurrent.
- •3. Patients suffering from cancer of Brenner or borderline ovarian cancer.
- •4. Patients who have not previously received any type of chemotherapy ...
- •5. Patients who have previously received a cumulative dose of Doxorubicin > 350 mg/m2 and/or Epirubicin > 540 mg/m2.
- •6. patients who have history of allergy to anthracycline and/or eggs ...
- •7. Patients suffering from cardiovascular disease.
- •8. Patients with Hemoglobin < 9 g/dl; WBCs < 1500/l; Platelets < 100,000//l; Creatinine > 1.5 mg/dl; SGOT, SGPT > 1.5 5times higher than normal.
- •9. Patients affettti from serious illnesses for which the administration of chemotherapy would expose the patient at risk too high.
- •10. patients who refused to sign the consent form.
研究者
相似试验
进行中（未招募）
不适用
ON PEGILATED LIPOSOMIAL DOXORUBICIN (TLC D-99) IN ASSOCIATION WITH IFOSFAMIDE IN PATIENTS WITH METASTATIC SOFT TISSUE SARCOMA - NDMETASTATIC SOFT TISSUE SARCOMASMedDRA version: 9.1Level: HLGTClassification code 10041299Term: Soft tissue sarcomasEUCTR2008-003316-36-ITCENTRO DI RIFERIMENTO ONCOLOGICO DI AVIANO
招募中
2 期
A Phase II Trial of Liposomal Doxorubicin (PLD, DOXILTM) as 3rd Line Treatment in Relapsed, Plutinum - resistant Ovarian CancerOvarian CancerJPRN-UMIN000002814Osaka University Faculty of Medicine Department of obstetrics and gynecology43
进行中（未招募）
不适用
Pegylated Liposomal Doxorubicin (Caleyx) in combination with Herceptin and Taxotere as first-line chemotherapy in metastatic breast cancer patients: A 2 stage Phase II, open label, Multicenter study.EUCTR2004-003989-15-ITSCHERING-PLOUGH
进行中（未招募）
不适用
iposomial doxorubicin Investigational chemotherapy - Tissue doppler imaging -EvaluatioFirst line treatment on female breast cancerMedDRA version: 6.1Level: PTClassification code 10006199EUCTR2005-003092-20-ITPOLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
进行中（未招募）
不适用
'Pilot trial of Pegilated Liposomal Doxorrubicin (Caelyx) in combination with Docetaxel (Taxotere) in advanced breast cancer patients'Estudio Piloto de Doxorrubicina Liposomal Pegilada (Caelyx) en combinación con Docetaxel (Taxotere) en pacientes con cáncer de mama avanzadoAdvanced Breast CancerEUCTR2005-001499-10-ESDr. José Ramón Mel Lorenzo